Compare EVN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVN | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.8M | 320.1M |
| IPO Year | 1998 | 2021 |
| Metric | EVN | LYEL |
|---|---|---|
| Price | $10.42 | $11.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | 60.7K | ★ 92.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8,712.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.09 | $11.47 |
| 52 Week High | $11.26 | $45.00 |
| Indicator | EVN | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 31.99 | 35.26 |
| Support Level | $10.33 | $11.59 |
| Resistance Level | $11.16 | $14.14 |
| Average True Range (ATR) | 0.11 | 0.81 |
| MACD | -0.03 | -0.30 |
| Stochastic Oscillator | 6.00 | 4.37 |
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.